Oncoinvent Asa · OSL:ONCIN
Oncoinvent Asa — Q3 2026 Earnings Presentation
21 slides from Oncoinvent Asa's earnings presentation, Oct 28, 2026
Slide 1: 3Q Company update
Transforming cancer care through direct alpha therapy 3Q Company update 28 October 2026 · Euronext Oslo: ONCIN
Slide 2: Today’s presenters
Today’s presenters Oystein Soug Ramzi Amri Zuzana Jirakova Trnkova Chief Executive Officer Chief Financial Officer Chief Medical Officer Q3 2026 2
Slide 3: Disclaimer and important information
Disclaimer and important information This presentation (the “Presentation”) has been prepared by Oncoinvent ASA (the “Company”) for information purposes only and does not constitute, and should not be construed as, an offer to sell, or a solicitation of an offer to buy, any securities of the Company
Slide 4: What we will cover today
What we will cover today 1 Highlights and operational update Delivering against our 2026 priorities CFO 2 Introduction New Chief Medical Officer CMO 3 Value proposition, Phase 3 preparation Radspherin and the opportunity CEO 4
Slide 5: Continued strong momentum and operational execution
HIGHLIGHTS Continued strong momentum and operational execution Radspherin® 71 11 1 3 Patients Clinical sites Publication Abstracts presented Recruited by end 3Q*, 1 new site added during Normal tissue dosimetry ESMO and EANM ~2/3 of total population 3Q results in Journal of Congresses Nuclear Medici
Slide 6: Delivering against our 2026 priorities
HIGHLIGHTS Delivering against our 2026 priorities ✓ Build momentum in Phase 2 Crossed halfway mark and close to 2/3 DELIVERED recruitment recruited,Q3 joins Q2 as best quarters so far Five sites added in YTD: Italy, UK, Spain (2), ✓ Expand the trial site network DELIVERED Belgium. Eleven now active,
Slide 7: Patient recruitment momentum continues to accelerate
CLINICAL PROGRESS Patient recruitment momentum continues to accelerate Patients recruited, incl. safety run-in, as of 30 September 2026 71 44 16 11 Patients recruited YTD recruitment Q3 recruitment Active sites To date, past halfway Close to double full year On par with best quarter Five new sites a
Slide 8: The raise takes the company to the April interim readout and funds Phase 3 readiness
FINANCING The raise takes the company to the April interim readout and funds Phase 3 readiness NOK 148.5m Efficacy data Into 2H 2027 Raised in September 2026 April interim readout Cash runway Gross proceeds 2x patients with ≥9 months Beyond April interim readout follow-up Phase 2 Regulators and Phas
Slide 9: What we will cover today
AGENDA What we will cover today 1 Highlights and operational update Delivering against our 2026 priorities CFO 2 Introduction New Chief Medical Officer CMO 3 Value proposition, Phase 3 preparation Radspherin and the opportunity CEO Q3 2026 9
Slide 10: Dr Zuzana Jirakova Trnkova as new Chief Medical Officer
LEADERSHIP Dr Zuzana Jirakova Trnkova as new Chief Medical Officer Q3 2026 10
Slide 11: Ovarian Cancer – High Unmet Medical Need Remains
LEADERSHIP Ovarian Cancer – High Unmet Medical Need Remains AFTER SURGERY YET THE CAUSE No visible Up to No visible disease 8 in 10 disease Most women with women relapse Peritoneal advanced ovarian cancer micrometastases drive leave surgery with no relapse in ovarian cancer visible disease Q3 2026 1
Slide 12: Ovarian Cancer – High Unmet Medical Need Remains
LEADERSHIP Ovarian Cancer – High Unmet Medical Need Remains AFTER SURGERY YET THE CAUSE No visible Up to No visible disease 8 in 10 disease Most women with women relapse Peritoneal advanced ovarian cancer micrometastases drive leave surgery with no relapse in ovarian cancer visible disease What if “
Slide 13: Why I joined Oncoinvent
LEADERSHIP Why I joined Oncoinvent WHY OVARIAN CANCER WHY RADSPHERIN® WHY ME • One of the deadliest • Many failed therapeutic 20+ years of experience gynecologic cancers approaches in ovarian • Strategic, medical, cancer operational and • Survival in advanced • Platinum chemotherapy regulatory disea
Slide 14: What we will cover today
AGENDA What we will cover today 1 Highlights and operational update Delivering against our 2026 priorities CFO 2 Introduction New Chief Medical Officer CMO 3 Value proposition, Phase 3 preparation Radspherin and the opportunity CEO Q3 2026 14
Slide 15: Oncoinvent: aiming to transform cancer care through direct alpha therapy
RADSPHERIN® Oncoinvent: aiming to transform cancer care for patients through direct alpha therapy Cancer in the abdominal cavity is an area with high unmet need and few good treatment options Q3 2026 15
Slide 16: Oncoinvent: aiming to transform cancer care through direct alpha therapy
RADSPHERIN® Oncoinvent: aiming to transform cancer care for patients through direct alpha therapy Oncoinvent develops Radspherin®, a receptor- Cancer in the abdominal cavity is an independent alpha radiopharmaceutical that area with high unmet need and few eradicates cancer cells in the abdominal go
Slide 17: Randomized interim data: Phase 2 data planned for late 2026 and March/April 2027
CLINICAL PROGRESS Randomized interim data Phase 2 data planned for late 2026 and March/April 2027 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Phase 1 Colorectal Phase 1/2a Ovarian Phase 2 Interim Interim Interim Final (safety) (efficacy) (>9mth FU) Submission Colorectal Phase 2 target: 2030 Ovar
Slide 18: Randomized Phase 2 study in first-line treatment of ovarian cancer
CLINICAL PROGRESS Randomized Phase 2 study in first-line treatment of ovarian cancer Treatment arm (N=60 PP) Follow-up SoC + Radspherin® Imaging every 3 months Completed Ongoing 2:1 up to 24 months Safety run-in Randomized cohort Long-term follow-up for up to 5 years for progression and survival Con
Slide 19: We raised towards Phase 3 readiness, supported by an efficacy readout
CLINICAL PROGRESS We raised towards phase 3 readiness, supported by an efficacy readout with twice as many evaluable patients 4Q 2026 FOLLOW-UP APRIL 2027 Interim safety readout Efficacy matures Interim efficacy readout Adverse events mostly appear Patients enter with no visible Reading out too earl
Slide 20: Looking ahead: Phase 3 readiness
OUTLOOK Looking ahead: Phase 3 readiness Partnering readiness Preparing for Manufacturing partnerships and readiness strategic Scaling production collaborations Regulatory capacity and readiness progressing CDMO selection and tech Early engagement with transfer readiness Trial readiness regulators,
Slide 21: Upcoming events: meet the team
OUTLOOK Upcoming events: meet the team 2026 2027 9-11 16-19 23 2-4 11-14 November November November December January BioEurope Jefferies week DNB Healthcare TRP JPM week conference 8th Targeted Radiopharmaceuticals Summit Europe Cologne London Oslo London San Francisco Q3 2026 21